^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MLL rearrangement

    i
    Other names: HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Methyltransferase 2A, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, Lysine Methyltransferase 2A, MLL, Myeloid/Lymphoid Or Mixed-Lineage Leukemia, KMT2A
    Apply
    Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia (AALL1621) (NCT02981628)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    06/19/2017
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    KMT2A • CD22
    |
    MLL rearrangement • CD22 expression
    |
    cytarabine • cyclophosphamide • methotrexate • Besponsa (inotuzumab ozogamicin) • vincristine • leucovorin calcium • mercaptopurine delayed release (DR6MP) • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) • cyclophosphamide intravenous • Starasid (cytarabine ocfosfate)
    A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia (NCT05761171)
    Phase 2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/08/2024
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    KMT2A
    |
    MLL rearrangement
    |
    cytarabine • methotrexate • vincristine • Revuforj (revumenib) • fludarabine IV • Oncaspar liquid (pegaspargase) • Asparlas (calaspargase pegol-mknl) • Starasid (cytarabine ocfosfate)
    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (APAL2020SC) (NCT04726241)
    Phase 1/2
    LLS PedAL Initiative, LLC
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    KMT2A
    |
    KMT2A rearrangement • MLL rearrangement
    Orphan Indications for CD19 Redirected Autologous T Cells (NCT04276870)
    Phase 2
    Stephan Grupp MD PhD
    Recruiting
    Last update posted :
    01/30/2025
    Initiation :
    03/12/2020
    Primary completion :
    03/10/2028
    Completion :
    03/10/2037
    CD19 • KMT2A
    |
    MLL rearrangement • CD19 expression
    |
    Kymriah (tisagenlecleucel-T)
    Umbilical Cord Blood Transplantation From Unrelated Donors (NCT03016806)
    Phase 1
    University of Rochester
    Recruiting
    Last update posted :
    08/19/2024
    Initiation :
    06/01/2015
    Primary completion :
    06/01/2025
    Completion :
    06/01/2026
    FLT3 • KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan • cyclophosphamide intravenous
    T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia (NCT01860937)
    Phase 1
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    05/01/2013
    Primary completion :
    05/01/2025
    Completion :
    05/01/2025
    KMT2A • IKZF1
    |
    MLL rearrangement • IKZF1 deletion
    |
    cyclophosphamide • vadacabtagene leraleucel (JCAR015)
    CARPALL: Immunotherapy With CD19/22 CAR T-cells for CD19+ Haematological Malignancies (NCT02443831)
    Phase 1
    University College, London
    Active, not recruiting
    Last update posted :
    05/30/2024
    Initiation :
    04/01/2016
    Primary completion :
    12/31/2028
    Completion :
    12/31/2036
    ABL1 • BCR • KMT2A • IGH • CD22 • TCF3
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cyclophosphamide • fludarabine IV • AUTO1/22 • cyclophosphamide intravenous
    A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance (NCT03114865)
    Phase 1/2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Active, not recruiting
    Last update posted :
    05/27/2024
    Initiation :
    09/05/2017
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    KMT2A
    |
    MLL rearrangement
    |
    Blincyto (blinatumomab) • dexamethasone
    Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders (NCT04644016)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    05/24/2024
    Initiation :
    11/20/2020
    Primary completion :
    12/20/2025
    Completion :
    12/20/2025
    KMT2A
    |
    MLL rearrangement • MLL rearrangement
    |
    clofarabine • fludarabine IV • busulfan • cyclosporin A microemulsion
    Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse (NCT01995578)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    05/22/2024
    Initiation :
    12/01/2013
    Primary completion :
    09/27/2023
    Completion :
    09/27/2023
    FLT3 • KMT2A
    |
    FLT3 mutation • MLL rearrangement
    |
    azacitidine
    A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation (AUGMENT-101) (NCT04065399)
    Phase 1/2
    Syndax Pharmaceuticals
    Recruiting
    Last update posted :
    05/17/2024
    Initiation :
    11/05/2019
    Primary completion :
    12/01/2024
    Completion :
    12/01/2024
    KMT2A • NUP98
    |
    NPM1 mutation • MLL rearrangement • MLL rearrangement • NUP98 rearrangement
    |
    Revuforj (revumenib) • Tybost (cobicistat)
    A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia (NCT05326516)
    Phase 1
    Syndax Pharmaceuticals
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    03/09/2022
    Primary completion :
    05/01/2024
    Completion :
    06/01/2024
    KMT2A • NUP98
    |
    KMT2A rearrangement • MLL rearrangement
    |
    cytarabine • cyclophosphamide • Revuforj (revumenib)